Literature DB >> 9618278

Cathepsin D is a good candidate for the specific release of a stable hemorphin from hemoglobin in vivo: VV-hemorphin-7.

I Fruitier1, I Garreau, J M Piot.   

Abstract

Hemorphin peptides, issued from hemoglobin, are emerging as endogenous bioactive peptides derived from in vivo tissular degradation of hemoglobin. In order to find the enzymes which could be implicated in the in vivo release of these peptides, the major lysosomal enzyme cathepsin D was selected, and a study of its activity towards hemoglobin and hemorphins was performed. In this paper, it is shown that according to the primary specificity of cathepsin D towards hemoglobin, this enzyme could constitute a good candidate for the in vivo release of two hemorphins: LVV-hemorphin-7 and VV-hemorphin-7. Moreover, these products, especially VV-hemorphin-7, are resistant to an extended cleavage by the enzyme. Although LVV-hemorphin-7 exhibits a lower resistance, an extended incubation with cathepsin D led to the release of the stable peptide VV-hemorphin-7.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618278     DOI: 10.1006/bbrc.1998.8614

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Hemoglobin-derived peptides as novel type of bioactive signaling molecules.

Authors:  Ivone Gomes; Camila S Dale; Kimbie Casten; Miriam A Geigner; Fabio C Gozzo; Emer S Ferro; Andrea S Heimann; Lakshmi A Devi
Journal:  AAPS J       Date:  2010-09-02       Impact factor: 4.009

Review 2.  Analysis of mouse brain peptides using mass spectrometry-based peptidomics: implications for novel functions ranging from non-classical neuropeptides to microproteins.

Authors:  Lloyd D Fricker
Journal:  Mol Biosyst       Date:  2010-04-28

3.  Identification and functional characterization of hemorphins VV-H-7 and LVV-H-7 as low-affinity agonists for the orphan bombesin receptor subtype 3.

Authors:  Hans-Peter Lammerich; Annette Busmann; Christian Kutzleb; Martin Wendland; Petra Seiler; Claudia Berger; Peter Eickelmann; Markus Meyer; Wolf-Georg Forssmann; Erik Maronde
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

4.  Molecular insights into the interaction of hemorphin and its targets.

Authors:  Amanat Ali; Bincy Baby; Soja Saghar Soman; Ranjit Vijayan
Journal:  Sci Rep       Date:  2019-10-14       Impact factor: 4.379

Review 5.  Dysregulation in erythrocyte dynamics caused by SARS-CoV-2 infection: possible role in shuffling the homeostatic puzzle during COVID-19.

Authors:  Michelle Mendanha Mendonça; Kellen Rosa da Cruz; Denise da Silva Pinheiro; Gean Carlos Alves Moraes; Patricia Maria Ferreira; Marcos Luiz Ferreira-Neto; Eduardo Sérgio da Silva; Reggiani Vilela Gonçalves; Gustavo Rodrigues Pedrino; James O Fajemiroye; Carlos Henrique Xavier
Journal:  Hematol Transfus Cell Ther       Date:  2022-01-25

Review 6.  Hemorphins-From Discovery to Functions and Pharmacology.

Authors:  Przemyslaw Mielczarek; Kinga Hartman; Anna Drabik; Hao-Yuan Hung; Eagle Yi-Kung Huang; Ewa Gibula-Tarlowska; Jolanta H Kotlinska; Jerzy Silberring
Journal:  Molecules       Date:  2021-06-25       Impact factor: 4.411

7.  Proteolytic characteristics of cathepsin D related to the recognition and cleavage of its target proteins.

Authors:  Huiying Sun; Xiaomin Lou; Qiang Shan; Ju Zhang; Xu Zhu; Jia Zhang; Yang Wang; Yingying Xie; Ningzhi Xu; Siqi Liu
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.